BIOFLOW-DAPT: Orsiro Mission Proven to be Safe and Effective with 1-month DAPT

Published: 12 Dec 2023

  • Views:

    Views Icon 434
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

Prof Marco Valgimigli (Istituto Cardiocentro Ticino, CH), principal investigator of the BIOFLOW-DAPT trial, discusses the design, outcomes and implications of this non-inferiority trial for 1-month DAPT regimen in high bleeding risk patients.

This video is supported by


You must be to comment. If you are not registered, you can register here.